2152Multicenter randomized clinical trial of the efficacy and safety of intravenous quercetin in patients with ST-elevation acute myocardial infarction

Пархоменко, А Н; Kozhukhov, Sergey; Lutay, Yaroslav

doi:10.1093/eurheartj/ehy565.2152

Cited by 9 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 61 A multicenter randomized clinical trial in Ukraine verified that intravenous administration of quercetin was safe and well tolerated to prevent reperfusion-induced limited infarct size and first anterior wall ST-segment elevation myocardial infarction. 62 Intravenous administration of 450 mg of quercetin was recommended and safer for reducing clinical severity in acute decompensated heart failure patients compared to 800 mg of quercetin over 5 days. 63 …”

Section: Safety Of Quercetin Use In Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

The therapeutic potential of quercetin for cigarette smoking–induced chronic obstructive pulmonary disease: a narrative review

Ding

Jiang

Zhan

et al. 2023

Ther Adv Respir Dis

View full text Add to dashboard Cite

Quercetin is a flavonoid with antioxidant and anti-inflammatory properties. Quercetin has potentially beneficial therapeutic effects for several diseases, including cigarette smoking–induced chronic obstructive pulmonary disease (CS-COPD). Many studies have shown that quercetin’s antioxidant and anti-inflammatory properties have positive therapeutic potential for CS-COPD. In addition, quercetin’s immunomodulatory, anti-cellular senescence, mitochondrial autophagy–modulating, and gut microbiota–modulating effects may also have therapeutic value for CS-COPD. However, there appears to be no review of the possible mechanisms of quercetin for treating CS-COPD. Moreover, the combination of quercetin with common therapeutic drugs for CS-COPD needs further refinement. Therefore, in this article, after introducing the definition and metabolism of quercetin, and its safety, we comprehensively presented the pathogenesis of CS-COPD related to oxidative stress, inflammation, immunity, cellular senescence, mitochondrial autophagy, and gut microbiota. We then reviewed quercetin’s anti-CS-COPD effects, performed by influencing these mechanisms. Finally, we explored the possibility of using quercetin with commonly used drugs for treating CS-COPD, providing a basis for future screening of excellent drug combinations for treating CS-COPD. This review has provided meaningful information on quercetin’s mechanisms and clinical use in treating CS-COPD.

show abstract

Section: Safety Of Quercetin Use In Diseasesmentioning

confidence: 99%

“… 62 Intravenous administration of 450 mg of quercetin was recommended and safer for reducing clinical severity in acute decompensated heart failure patients compared to 800 mg of quercetin over 5 days. 63 …”

Section: Safety Of Quercetin Use In Diseasesmentioning

confidence: 99%

The therapeutic potential of quercetin for cigarette smoking–induced chronic obstructive pulmonary disease: a narrative review

Ding

Jiang

Zhan

et al. 2023

Ther Adv Respir Dis

View full text Add to dashboard Cite

show abstract

“…An open-label clinical trial conducted in Ukraine studied the administration of intravenous quercetin (Corvitin) over 10 days in patient admitted with an acute myocardial infarction and heart failure symptoms. After 3 days, there was a significant improvement in their profile of cardiac biomarkers and LVEF ( 157 ). Altogether, these clinical data suggest that quercetin has potential cardioprotective effects, and form a solid foundation for a potential application of quercetin in the prevention of IHD and its complications.…”

Section: Cardiovascular Protective Properties Of Quercetinmentioning

confidence: 99%

Therapeutic Potential of Quercetin to Alleviate Endothelial Dysfunction in Age-Related Cardiovascular Diseases

Dagher

Mury

Thorin‐Trescases

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

The vascular endothelium occupies a catalog of functions that contribute to the homeostasis of the cardiovascular system. It is a physically active barrier between circulating blood and tissue, a regulator of the vascular tone, a biochemical processor and a modulator of coagulation, inflammation, and immunity. Given these essential roles, it comes to no surprise that endothelial dysfunction is prodromal to chronic age-related diseases of the heart and arteries, globally termed cardiovascular diseases (CVD). An example would be ischemic heart disease (IHD), which is the main cause of death from CVD. We have made phenomenal advances in treating CVD, but the aging endothelium, as it senesces, always seems to out-run the benefits of medical and surgical therapies. Remarkably, many epidemiological studies have detected a correlation between a flavonoid-rich diet and a lower incidence of mortality from CVD. Quercetin, a member of the flavonoid class, is a natural compound ubiquitously found in various food sources such as fruits, vegetables, seeds, nuts, and wine. It has been reported to have a wide range of health promoting effects and has gained significant attention over the years. A growing body of evidence suggests quercetin could lower the risk of IHD by mitigating endothelial dysfunction and its risk factors, such as hypertension, atherosclerosis, accumulation of senescent endothelial cells, and endothelial-mesenchymal transition (EndoMT). In this review, we will explore these pathophysiological cascades and their interrelation with endothelial dysfunction. We will then present the scientific evidence to quercetin's anti-atherosclerotic, anti-hypertensive, senolytic, and anti-EndoMT effects. Finally, we will discuss the prospect for its clinical use in alleviating myocardial ischemic injuries in IHD.

show abstract

“…Quercetin (Que), a natural polyphenol flavonoid recognized by the FDA as a Generally Recognized As Safe (GRAS) ingredient, holds substantial therapeutic potential for the treatment of various cardiovascular diseases owing to its potent antioxidant and anti‐inflammatory properties. [ 18 ] The antioxidant activity of Que is attributed to its ability to scavenge ROS, a process facilitated by its intrinsic antioxidant pharmacophores, such as the catechol group, the 2,3‐double bond, and the hydroxyl group in its heterocyclic ring. [ 19 ] Que has emerged as a cardioprotective agent against cardiac ischemia/reperfusion injury by inhibiting the inflammatory cascade and apoptosis through multiple signaling pathways, including PI3K/Akt pathway.…”

Section: Introductionmentioning

confidence: 99%

Inflammation‐Targeted Nanomedicines Alleviate Oxidative Stress and Reprogram Macrophages Polarization for Myocardial Infarction Treatment

Hu,

Li,

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Myocardial infarction (MI) is a critical global health challenge, with current treatments limited by the complex MI microenvironment, particularly the excessive oxidative stress and intense inflammatory responses that exacerbate cardiac dysfunction and MI progression. Herein, a mannan‐based nanomedicine, Que@MOF/Man, is developed to target the inflammatory infarcted heart and deliver the antioxidative and anti‐inflammatory agent quercetin (Que), thereby facilitating a beneficial myocardial microenvironment for cardiac repair. The presence of mannan on the nanoparticle surface enables selective internalization by macrophages rather than cardiomyocytes. Que@MOF/Man effectively neutralizes reactive oxygen species in macrophages to reduce oxidative stress and promote their differentiation into a reparative phenotype, reconciling the inflammatory response and enhancing cardiomyocyte survival through intercellular communication. Owing to the recruitment of macrophages into inflamed myocardium post‐MI, in vivo, administration of Que@MOF/Man in MI rats revealed the specific distribution into the injured myocardium compared to free Que. Furthermore, Que@MOF/Man exhibited favorable results in resolving inflammation and protecting cardiomyocytes, thereby preventing further myocardial remodeling and improving cardiac function in MI rats. These findings collectively validate the rational design of an inflammation‐targeted delivery strategy to mitigate oxidative stress and modulate the inflammation response in the injured heart, presenting a therapeutic avenue for MI treatment.

show abstract

2152Multicenter randomized clinical trial of the efficacy and safety of intravenous quercetin in patients with ST-elevation acute myocardial infarction

Cited by 9 publications

References 0 publications

The therapeutic potential of quercetin for cigarette smoking–induced chronic obstructive pulmonary disease: a narrative review

The therapeutic potential of quercetin for cigarette smoking–induced chronic obstructive pulmonary disease: a narrative review

Therapeutic Potential of Quercetin to Alleviate Endothelial Dysfunction in Age-Related Cardiovascular Diseases

Inflammation‐Targeted Nanomedicines Alleviate Oxidative Stress and Reprogram Macrophages Polarization for Myocardial Infarction Treatment

Contact Info

Product

Resources

About